Residency · Residency · Chronic Pain Management

Postherpetic Neuralgia: Prevention and Treatment

Introduction

Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (shingles) and one of the most frequently encountered neuropathic pain conditions in clinical practice. It is defined as pain persisting for 90 or more days after the onset of the herpes zoster rash. PHN affects approximately 10-18% of herpes zoster patients overall, though the incidence rises sharply with age. It represents a significant burden of suffering, particularly in elderly patients, and can persist for months to years.

Varicella Zoster Virus Reactivation

Primary infection with varicella zoster virus (VZV) causes chickenpox, after which the virus establishes lifelong latency in dorsal root ganglia and cranial nerve ganglia. When cell-mediated immunity declines — whether due to aging, immunosuppression, or other factors — the virus reactivates, replicating within the ganglion and traveling anterograde along sensory nerves to the corresponding dermatome, where it produces the characteristic unilateral vesicular rash.

The neural damage that sets the stage for PHN occurs through several mechanisms: direct viral cytopathology, intense inflammatory infiltration of the DRG and peripheral nerve, hemorrhagic necrosis of the ganglion, and Wallerian degeneration of sensory axons. Pathological studies reveal loss of both myelinated and unmyelinated fibers, DRG neuronal loss, dorsal horn atrophy, and scarring.

Mechanisms of PHN Pain

The pain of PHN arises from both peripheral and central changes. Peripheral sensitization results from ectopic discharge from damaged nociceptors and upregulation of sodium channels and TRPV1 receptors on surviving C-fibers. Deafferentation — the loss of large myelinated inhibitory fibers — produces disinhibition of dorsal horn neurons. Central sensitization follows, with dorsal horn neuronal hyperexcitability, expanded receptive fields, spontaneous activity, and wind-up. At higher levels, reorganization of the somatosensory cortex occurs, similar to that seen in other deafferentation pain states.

<image>Illustration of varicella zoster virus reactivation and pathogenesis of postherpetic neuralgia, showing: dormant VZV in a dorsal root ganglion neuron reactivating and traveling anterograde along a sensory axon to the skin producing vesicular eruption in a dermatomal distribution; inset showing the pathological changes in the DRG including inflammatory infiltrate, neuronal loss, and fibrosis; and the downstream effects on the peripheral nerve showing demyelination, axonal degeneration, and ectopic discharge from damaged nociceptors.</image>

Risk Factors for PHN Development

Age is the most significant risk factor: incidence rises from less than 5% in patients under 60 to more than 30% in those over 80. Severe acute zoster pain — particularly a prodromal and acute VAS above 6 — strongly predicts PHN development, as does greater severity of the rash (more vesicles, larger affected area). Ophthalmic (V1) zoster involving the trigeminal ophthalmic division carries a higher PHN risk. Immunosuppression from HIV, organ transplant, malignancy, or immunosuppressive therapy increases susceptibility. The presence of prodromal pain before rash onset is another predictor. Female sex and psychosocial factors such as depression and social isolation serve as additional risk modifiers.

Vaccination Impact

Zoster Vaccine Live (Zostavax)

This live attenuated VZV vaccine, approved for adults aged 50 and older, was studied in the Shingles Prevention Study, which found it reduced herpes zoster incidence by 51% and PHN incidence by 67% in adults over 60. However, its efficacy wanes over time, declining to approximately 20% at eight years. It is no longer available in the United States since 2020.

Recombinant Zoster Vaccine (Shingrix)

Shingrix is an adjuvanted recombinant glycoprotein E subunit vaccine — non-live — administered as a two-dose series at 0 and 2-6 months. It is recommended for adults aged 50 and older and immunocompromised adults aged 19 and older. The ZOE-50 and ZOE-70 trials demonstrated overall efficacy of 97% against herpes zoster and 91% against PHN in adults over 50, with efficacy remaining above 85% at seven-year follow-up. It is also effective in immunocompromised patients, including transplant recipients and those with hematologic malignancies, with modified schedules. Reactogenicity is notable: injection site pain occurs in 78% of recipients, myalgia in 45%, fatigue in 45%, and grade 3 reactions in approximately 10%.

Acute Zoster Treatment (PHN Prevention)

The cornerstone of acute zoster treatment is antiviral therapy: acyclovir (800 mg five times daily), valacyclovir (1000 mg three times daily), or famciclovir (500 mg three times daily) for seven days, initiated within 72 hours of rash onset. Antivirals reduce the duration and severity of acute zoster and may reduce PHN risk. Corticosteroids — prednisone 60 mg/day tapered over three weeks in combination with antivirals — reduce acute pain and accelerate rash healing, though they do not clearly prevent PHN. Aggressive acute pain management, including opioids if needed, may reduce central sensitization and subsequent PHN risk. Neural blockade during acute zoster — paravertebral or epidural blocks with local anesthetic and corticosteroid during the first 2-4 weeks — may reduce PHN incidence, although the evidence remains mixed.

Pharmacotherapy for Established PHN

First-Line Agents

Pregabalin (150-600 mg/day) is FDA-approved for PHN with an NNT of 4.2 and offers flexible, dose-related efficacy, though dizziness, somnolence, and edema are common side effects. Gabapentin (1800-3600 mg/day) has an NNT of 4.4 and requires slow titration; extended-release (Gralise) and gastroretentive (Horizant) formulations allow once-daily dosing. Tricyclic antidepressants — amitriptyline, nortriptyline, or desipramine at 25-150 mg/day — are among the most effective agents with an NNT of 2.6, but anticholinergic side effects and cardiac risks limit their use in the elderly, who constitute the primary PHN population. Nortriptyline and desipramine are preferred for their better tolerability. Duloxetine (60-120 mg/day), while not specifically FDA-approved for PHN, is widely used based on its broader neuropathic pain evidence.

Topical Agents

The lidocaine 5% patch (Lidoderm) is FDA-approved for PHN. Up to three patches are applied for 12 hours on and 12 hours off. It has minimal systemic absorption, an excellent safety profile in the elderly, and is particularly effective for allodynia, with an NNT of approximately 4. The capsaicin 8% patch (Qutenza) is also FDA-approved for PHN. A single 60-minute application depletes substance P and causes reversible defunctionalization of TRPV1-expressing C-fibers, with onset within 1-2 weeks and a duration of effect of approximately three months. Repeat applications are possible, though the NNT is 7.

<image>Diagram showing the pharmacotherapy ladder for postherpetic neuralgia treatment, organized in tiers: First tier showing pregabalin/gabapentin, TCAs, and lidocaine 5% patches with their respective NNT values and key side effects; Second tier showing duloxetine, capsaicin 8% patch, and combination therapy; Third tier showing tramadol, strong opioids (with caution), and interventional options. Arrows indicate progression from one tier to the next based on inadequate response or tolerability issues.</image>

Opioids

Tramadol (200-400 mg/day) has an NNT of approximately 5 and functions as a weak mu-opioid agonist with norepinephrine reuptake inhibitor activity; it is a second-line option. Strong opioids such as morphine and oxycodone are effective (NNT approximately 2.5) but carry significant risks of sedation, falls, constipation, and cognitive impairment in the elderly. They are reserved for refractory cases with careful monitoring and should be avoided as long-term monotherapy.

Interventional Approaches

Intercostal nerve blocks with local anesthetic and corticosteroid at the affected levels provide diagnostic and short-term therapeutic benefit. Paravertebral blocks offer broader coverage than intercostal blocks through injection in the paravertebral space at affected levels. Epidural steroid injections via transforaminal or interlaminar approach deliver local anesthetic and corticosteroid to the affected level. Pulsed radiofrequency of the DRG, applied at 42 degrees Celsius for 120 seconds at the affected ganglion, is a neuromodulatory (non-destructive) approach that several studies report provides 3-6 months of pain relief. Spinal cord stimulation may be considered for refractory PHN, and DRG stimulation may provide more targeted relief, though evidence is limited to case series. Intrathecal methylprednisolone is controversial — single-center studies from Japan showed dramatic efficacy (NNT 1.1) but the approach has not been widely adopted due to concerns about arachnoiditis and methodological limitations. Botulinum toxin type A injected subcutaneously in the affected area has an analgesic effect independent of muscle relaxation, possibly through inhibiting the release of pain mediators from nociceptors, and is supported by several randomized controlled trials.

<image>Clinical illustration showing the dermatomal distribution of postherpetic neuralgia affecting the T4-T5 dermatome on the left thorax, with characteristic post-zoster scarring and hyperpigmentation. Insets demonstrate: (A) lidocaine 5% patch application over the affected area, (B) fluoroscopic-guided intercostal nerve block technique with needle positioned at the inferior rib margin, and (C) pulsed radiofrequency electrode placement at the dorsal root ganglion under fluoroscopic guidance showing the needle tip in the superior neural foramen.</image>

Clinical Pearls

Vaccination is the single most effective strategy against PHN. Shingrix provides 91% protection and should be strongly recommended to all eligible patients. Early and aggressive pain control during acute zoster may reduce PHN risk by limiting central sensitization — acute zoster pain should never be undertreated. Lidocaine 5% patches are an ideal first-line option in elderly PHN patients because of their excellent safety profile and lack of systemic side effects, and they combine well with oral agents. TCAs remain among the most effective pharmacological agents for PHN, but they must be used cautiously in the elderly; starting with nortriptyline or desipramine at low doses (10-25 mg) and titrating slowly is the prudent approach. Combination therapy — a gabapentinoid plus a TCA, or a gabapentinoid plus a topical agent — is often necessary and should be considered early rather than after sequential monotherapy failures. Finally, PHN pain often improves over time: approximately 50% of patients experience significant improvement within one year, though a subset will develop intractable lifelong pain.

References

1. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1-S26.
2. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019-1032.
3. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.
4. Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Healthc. 2016;9:447-454.

Read this lecture as Markdown